Boehringer Ingelheim Investing in Mexico

Company is expanding at three production sites over the next three years.

Boehringer Ingelheim (BI) will be investing 1.6 billion Mexican pesos ($84 million) by 2023 to expand capacity at all three of its manufacturing locations in Mexico. This investment is in line with the company’s strategy to develop and manufacture more complex tablets for global launches at the $100 million R&D and manufacturing facility currently under construction in Germany and move its “older, easier-to-manufacture drugs” to other plants around the globe.


Of the 1.6 billion pesos to be spent in Mexico, 1 billion ($52 million) will be invested in the company’s site in Xochimilco, which produces diabetes medications. The investment, which will be made over the next two years, will be used to expand capacity and enable BI to increase exports to the United States and various Central and South American countries. BI’s goal is to eventually reach 2.5 billion tablets per year by 2028 at this facility (up from 1.6 billion today).


Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.